Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response
详细信息 查看全文
- 作者：Jueqiong Wang ; Congying Zhao ; Peng Kong ; Guanyun Bian ; Zhe Sun ; Yafei Sun ; Li Guo ; guoli6@163.com" class="auth_mail" title="E-mail the corresponding author ; Bin Li ; jack511@163.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：MS ; multiple sclerosis ; MB ; methylene blue ; EAE ; experimental autoimmune encephalomyelitis ; CNS ; central nervous system ; IFN ; interferon ; NF-κB ; nuclear factor kappa B ; AMPK ; AMP-activated protein kinase ; SIRT1 ; silent mating-type information regulation 2 homolog 1 ; NAD+ ; ; nicotinamide adenine dinucleotide ; MOG ; myelin oligodendrocyte glycoprotein peptide ; CFA ; complete Freund's adjuvant ; Th1 ; T helper type1 ; Th2 ; T helper type2 ; Th17 ; T helper type17 ; Tregs ; regulatory T cells ; STAT3 ; sign
- 刊名：Journal of Neuroimmunology
- 出版年：2016
- 出版时间：15 October 2016
- 年：2016
- 卷：299
- 期：Complete
- 页码：45-52
- 全文大小：1053 K
文摘
- •
We explored that MB treatment can lessen the severity EAE and hypothesized the mechanisms underlying its effects.
- •
MB treatment inhibited the development and progression of EAE and mitigated inflammation by reducing inflammatory infiltrates, demyelination and axonal loss.
- •
MB treatment inhibited inflammatory responses by activating the AMPK/SIRT1 pathway and suppressing the activation of NF-κB.
- •
MB treatment could modulate the Th17/Treg immune response to alleviate EAE.